GlassScriptPrepare for your visit
Pablo M Tebas
Infectious Disease · Philadelphia, PA · NPI 1659307346
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$159,800.52
in general payments reported to CMS, 2019-2025 · $12K in 2025
The $12K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Who reported paying
General payments only, top 5 by amount.
- Viiv Healthcare Company $94,280.92
- Merck Sharp & Dohme LLC $38,517.70
- Shionogi INC $22,156.84
- Gilead Sciences, INC. $4,760.91
- Biontech Se $84.15
Drugs and devices associated with these payments
Dovato Fetroja Cabenuva Rukobia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Pablo Tebas listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/28946/pablo-m-tebas